» Articles » PMID: 21136076

Different Immunohistochemical and Ultrastructural Phenotypes of Squamous Differentiation in Bladder Cancer

Overview
Journal Virchows Arch
Date 2010 Dec 8
PMID 21136076
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Besides worse prognosis of bladder cancer with squamous differentiation (pure squamous cell carcinoma (SCC) or mixed urothelial carcinoma (UC/SCC)), high-grade non-keratinising squamous differentiation is difficult to identify in haematoxylin-eosin stainings. This study aims to validate routine immunohistochemical markers for squamous differentiation in a larger cohort of patients. Tissue microarrays of 89 pure SCCs and mixed UC/SCCs, 66 urothelial carcinomas (UC), precursor lesions and normal urothelium were stained for cytokeratin (CK) 5/6, CK 5/14, CK 7, CK 20 and uroplakin III. Electron microscopy was performed to confirm the differentiation. Pure SCCs displayed staining throughout the epithelium for CK 5/6 (76.6% (36/47)) and CK 5/14 (95.8% (46/48)), focal staining for CK 7 (28.9% (13/45)) and no staining for CK 20 and uroplakin III (both 0% (0/48)). UCs exhibited a basal or diffuse staining for CK 5/6 (30.2% (16/53)) and CK 5/14 (57.1% (32/56)), focal positivity for CK 7 (83.6% (46/55)), CK 20 (50.9% (29/57)) and uroplakin III (21.8% (12/55)). Each marker discriminated SCC and UC significantly (p < 0.01). A third subgroup rarely showed full epithelial staining for CK 5/6 (14.3% (1/7)) and CK 5/14 (28.6% (2/7)), focal staining for CK 7 (85.7% (6/7)) and no staining for CK 20 and uroplakin III (both 0% (0/7)). Electron microscopy could prove both, SCC and UC characteristics, revealing a transient type. A staining pattern with CK 5/6- and CK 5/14-positivity plus CK 20- and uroplakin III-negativity identified squamous differentiation in bladder tumours and revealed a third type of squamous transdifferentiation.

Citing Articles

Dual role of GRHL3 in bladder carcinogenesis depending on histological subtypes.

Lammert F, Pannhausen J, Noetzel E, Friedland F, Wirtz J, Herfs Y Mol Oncol. 2024; 18(6):1397-1416.

PMID: 38429970 PMC: 11164254. DOI: 10.1002/1878-0261.13623.


The impact of squamous cell transformation on the prognosis of patients treated with radical nephroureterectomy.

Huang L, Chen C, Li J, Chiu K, Wang S, Yang C BMC Cancer. 2024; 24(1):247.

PMID: 38388388 PMC: 10885513. DOI: 10.1186/s12885-024-12010-5.


Hypercalcemia-leukocytosis syndrome from non-schistosomiasis-associated squamous cell carcinoma of the urinary bladder: a case report and review of the literature.

Chibuzo I, Healy R, Hatimy U, Tang V J Med Case Rep. 2023; 17(1):133.

PMID: 37041610 PMC: 10091549. DOI: 10.1186/s13256-023-03860-x.


Primary urethral carcinoma with variant histology: A case report and literature review.

Liu M, Xu S, He J, Mu Y, Chen K, Zhang W Mol Clin Oncol. 2022; 17(4):142.

PMID: 36157318 PMC: 9468807. DOI: 10.3892/mco.2022.2575.


Molecular profile of pure squamous cell carcinoma of the bladder identifies major roles for OSMR and YAP signalling.

Hurst C, Cheng G, Platt F, Alder O, Black E, Burns J J Pathol Clin Res. 2022; 8(3):279-293.

PMID: 35289095 PMC: 8977277. DOI: 10.1002/cjp2.261.


References
1.
Gee J, Montoya R, Khaled H, Sabichi A, Grossman H . Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol. 2003; 21(4):266-70. DOI: 10.1016/s1078-1439(02)00271-5. View

2.
Chu P, Wu E, Weiss L . Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000; 13(9):962-72. DOI: 10.1038/modpathol.3880175. View

3.
Moll R, Lowe A, Laufer J, Franke W . Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol. 1992; 140(2):427-47. PMC: 1886432. View

4.
Moll R, Wu X, Lin J, Sun T . Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am J Pathol. 1995; 147(5):1383-97. PMC: 1869506. View

5.
Shanks J, Iczkowski K . Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics. Histopathology. 2009; 54(7):885-900. DOI: 10.1111/j.1365-2559.2008.03167.x. View